Literature DB >> 27564280

Does an asymmetric lobe in digital rectal examination include any risk for prostate cancer? results of 1495 biopsies.

Ömer Yilmaz1, Özgür Kurul1, Ferhat Ates1, Hasan Soydan1, Zeki Aktas1.   

Abstract

INTRODUCTION: Despite the well-known findings related to malignity in DRE such as nodule and induration, asymmetry of prostatic lobes, seen relatively, were investigated in a few studies as a predictor of prostate cancer so that there is no universally expected conclusion about asymmetry. We aimed to compare cancer detection rate of normal, asymmetric or suspicious findings in DRE by using biopsy results.
MATERIALS AND METHODS: Data of 1495 patients underwent prostate biopsy between 2006-2014 were searched retrospectively. Biopsy indications were abnormal DRE and or elevated PSA level( >4ng/mL). DRE findings were recorded as Group 1: Benign DRE, Group 2: Asymmetry and Group 3: Nodule/induration. Age, prostatic volume , biopsy results and PSA levels were recorded.
RESULTS: Mean age, prostate volume and PSA level were 66.72, 55.98 cc and 18.61ng/ mL respectively. Overall cancer detection rate was 38.66 % (575 of 1495). PSA levels were similar in group 1 and 2 but significantly higher in group 3. Prostatic volume was similar in group 1 and 2 and significantly lower in Group 3. Malignity detection rate of group 1,2 and 3 were 28.93%, 34.89% and 55.99% respectively. Group 1 and 2 were similar (p=0.105) but 3 had more chance for cancer detection.
CONCLUSION: Nodule is the most important finding in DRE for cancer detection. Only na asymmetric prostate itself does not mean malignity. Copyright© by the International Brazilian Journal of Urology.

Entities:  

Keywords:  Digital Rectal Examination; Neoplasms; Prostate

Mesh:

Substances:

Year:  2016        PMID: 27564280      PMCID: PMC5006765          DOI: 10.1590/S1677-5538.IBJU.2014.0598

Source DB:  PubMed          Journal:  Int Braz J Urol        ISSN: 1677-5538            Impact factor:   1.541


  17 in total

1.  Prostatic asymmetry as a risk factor for prostatic carcinoma: serial prostate-specific antigen monitoring and cancer detection.

Authors:  J G Hansen; B L Dalkin; C H Harris; C S Johnson; F R Ahmann
Journal:  Br J Urol       Date:  1997-06

2.  Understanding the relationship between tumor size, gland size, and disease aggressiveness in men with prostate cancer.

Authors:  Michael A Kozminski; Ganesh S Palapattu; Rohit Mehra; Jeffrey S Montgomery; Alon Z Weizer; Ted A Skolarus; Brent K Hollenbeck; David C Miller; Chang He; Scott Tomlins; James E Montie; Felix Y Feng; David P Wood; Lakshmi P Kunju; Todd M Morgan
Journal:  Urology       Date:  2014-06-21       Impact factor: 2.649

3.  Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial.

Authors:  Paul F Pinsky; Barnett S Kramer; E David Crawford; Robert L Grubb; Donald A Urban; Gerald L Andriole; David Chia; David L Levin; John K Gohagan
Journal:  Urology       Date:  2006-08       Impact factor: 2.649

4.  Impact of PSA and DRE on histologic findings at prostate biopsy in Turkish men over 75 years of age.

Authors:  Levent Verim; Asif Yildirim; Erem Kaan Basok; Erol Peltekoglu; Eyup Sabri Pelit; Ebru Zemheri; Resit Tokuc
Journal:  Asian Pac J Cancer Prev       Date:  2013

5.  The digital rectal examination (DRE) remains important - outcomes from a contemporary cohort of men undergoing an initial 12-18 core prostate needle biopsy.

Authors:  Ricardo Palmerola; Paul Smith; Vanessa Elliot; Carl T Reese; Frank B Mahon; Lewis E Harpster; Nikolina Icitovic; Jay D Raman
Journal:  Can J Urol       Date:  2012-12       Impact factor: 1.344

6.  The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancer.

Authors:  C Gosselaar; R Kranse; M J Roobol; S Roemeling; F H Schröder
Journal:  Prostate       Date:  2008-06-15       Impact factor: 4.104

7.  Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.

Authors:  William J Catalona; Jerome P Richie; Frederick R Ahmann; M'Liss A Hudson; Peter T Scardino; Robert C Flanigan; Jean B DeKernion; Timothy L Ratliff; Louis R Kavoussi; Bruce L Dalkin; W Bedford Waters; Michael T MacFarlane; Paula C Southwick
Journal:  J Urol       Date:  1994-05       Impact factor: 7.450

8.  Prevalence and pathological extent of prostate cancer in men with prostate specific antigen levels of 2.9 to 4.0 ng./ml.

Authors:  J W Colberg; D S Smith; W J Catalona
Journal:  J Urol       Date:  1993-03       Impact factor: 7.450

Review 9.  Androgen receptor roles in the development of benign prostate hyperplasia.

Authors:  Kouji Izumi; Atsushi Mizokami; Wen-Jye Lin; Kuo-Pao Lai; Chawnshang Chang
Journal:  Am J Pathol       Date:  2013-04-06       Impact factor: 4.307

10.  Inhibitors of apoptosis proteins in experimental benign prostatic hyperplasia: effects of serenoa repens, selenium and lycopene.

Authors:  Letteria Minutoli; Domenica Altavilla; Herbert Marini; Mariagrazia Rinaldi; Natasha Irrera; Gabriele Pizzino; Alessandra Bitto; Salvatore Arena; Sebastiano Cimino; Francesco Squadrito; Giorgio Ivan Russo; Giuseppe Morgia
Journal:  J Biomed Sci       Date:  2014-03-10       Impact factor: 8.410

View more
  1 in total

Review 1.  Digital Rectal Examination for Prostate Cancer Screening in Primary Care: A Systematic Review and Meta-Analysis.

Authors:  Leen Naji; Harkanwal Randhawa; Zahra Sohani; Brittany Dennis; Deanna Lautenbach; Owen Kavanagh; Monica Bawor; Laura Banfield; Jason Profetto
Journal:  Ann Fam Med       Date:  2018-03       Impact factor: 5.166

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.